About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker ABBV · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026A Study to Assess the Adverse Events and How Oral ABBV-1606 Moves Through the Body of Healthy Adult…
NCT07935564 · Healthy Volunteer
ABBV-1606, Placebo
ABBV
AbbVie
Phase 1Not yet recruiting40Jul 2027Registry ↗
Nov 13, 2026Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adul…
NCT07680686 · Healthy Volunteer
Ubrogepant, Ubrogepant
ABBV
AbbVie
Phase 1Completed
was active, not recruiting
52Oct 16, 2026Registry ↗
Nov 13, 2026A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and A…
NCT05889182 · Hidradenitis Suppurativa
Upadacitinib, Placebo
ABBV
AbbVie
Phase 3Active, not recruiting1,328Aug 2028Registry ↗
Nov 13, 2026Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or…
NCT03850782 · Open-Angle Glaucoma, Ocular Hypertension
Bimatoprost (SR)
ABBV
AbbVie
Phase 3Completed515Aug 8, 2025Registry ↗
Nov 12, 2026A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe Psoriasis
NCT07933536 · Moderate to Severe Psoriasis
Risankizumab, ABBV-295
ABBV
AbbVie
Phase 2Not yet recruiting105Dec 2028Registry ↗
Nov 12, 2026M4 Receptor PET Radioligand Validation Study in Healthy Adults
NCT07933497 · Healthy Volunteers
[11C]ABBV-112i
ABBV
AbbVie
Early phase 1Not yet recruiting6Feb 2027Registry ↗
Nov 12, 2026A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Ad…
NCT07933211 · Systemic Sclerosis
ABBV-722, Upadacitinib
ABBV
AbbVie
Phase 2/3Not yet recruiting580Jun 2035Registry ↗
Nov 12, 2026An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Ad…
NCT06023030 · Crohn's Disease
ABBV
AbbVie
—Completed
was recruiting
253Sep 11, 2026Registry ↗
Nov 10, 2026Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthr…
NCT07904754 · Rheumatoid Arthritis
ABBV-722, Upadacitinib
ABBV
AbbVie
Phase 2Not yet recruiting250Jul 2029Registry ↗
Nov 10, 2026Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participan…
NCT07227896 · Parkinson's Disease
ABBV
AbbVie
—Recruiting100Oct 2027Registry ↗
Nov 10, 2026A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Partic…
NCT05650632 · Multiple Myeloma
Etentamig (ABBV-383)
ABBV
AbbVie
Phase 1Recruiting250Aug 2029Registry ↗
Nov 9, 2026A Study to Assess How Intravenous and Subcutaneous Administrations of Trosunilimab Move Through the…
NCT07925983 · Healthy Volunteer
Trosunilimab, Trosunilimab
ABBV
AbbVie
Phase 1Recruiting60May 2027Registry ↗
Nov 9, 2026A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of…
NCT07514260 · Healthy Volunteer
ABBV-295, Placebo for ABBV-295
ABBV
AbbVie
Phase 1Active, not recruiting24Dec 2026Registry ↗
Nov 9, 2026Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
NCT06865105 · Psoriatic Arthritis
Lutikizumab, Risankizumab
ABBV
AbbVie
Phase 2Recruiting300Aug 2029Registry ↗
Nov 9, 2026An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adul…
NCT05827887 · Migraine
ABBV
AbbVie
—Completed226Jan 28, 2026Registry ↗
Nov 6, 2026A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Bo…
NCT06032546 · Human Immuno-deficiency Virus (HIV) Disease
Budigalimab, Placebo for Budigalimab
ABBV
AbbVie
Phase 2Terminated163Sep 22, 2025Registry ↗
Nov 6, 2026Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activi…
NCT05959083 · Atopic Dermatitis (AD)
ABBV
AbbVie
—Completed200May 7, 2026Registry ↗
Nov 6, 2026Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With…
NCT05296447 · Diabetic Retinopathy, DR
Standard of Care, Aflibercept
ABBV
AbbVie
Phase 2Active, not recruiting
was enrolling by invitation
103Jun 2031Registry ↗
Nov 5, 2026A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and Onabotulinum…
NCT07871513 · Upper Facial Lines, Glabellar Lines
TrenibotulinumtoxinE and OnabotulinumtoxinA, Placebo
ABBV
AbbVie
Phase 2Recruiting300Jun 2028Registry ↗
Nov 5, 2026A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult…
NCT07649954 · Healthy Volunteer
Nacresertib, Itraconazole
ABBV
AbbVie
Phase 1Completed
was active, not recruiting
12Oct 5, 2026Registry ↗
Nov 5, 2026A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult…
NCT07291232 · Obesity
ABBV-295, Placebo
ABBV
AbbVie
Phase 1Active, not recruiting
was recruiting
80Apr 2027Registry ↗
Nov 4, 2026Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through t…
NCT05753501 · Hematologic Cancer
ABBV-101
ABBV
AbbVie
Phase 1Active, not recruiting135Mar 2031Registry ↗
Nov 3, 2026Expanded Access to Tavapadon
NCT07158827 · Parkinson Disease
Tavapadon
ABBV
AbbVie
—No longer available
was available
——Registry ↗
Nov 3, 2026Expanded Access to Venetoclax
NCT03123029 · Relapsed/Refractory Lymphoid Malignancies, Relapsed/Refract…
Venetoclax
ABBV
AbbVie
—Available——Registry ↗
Nov 2, 2026A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adul…
NCT07756580 · Glabellar Lines
AGN-151586, BOTOX
ABBV
AbbVie
Phase 1Active, not recruiting
was recruiting
143Feb 2027Registry ↗
Nov 2, 2026A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerat…
NCT01848561 · Ulcerative Colitis (UC)
ABBV
AbbVie
—Completed
was active, not recruiting
8,250Sep 30, 2026Registry ↗
Oct 29, 2026A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults
NCT07856706 · Healthy Subjects
ABBV-7828, Placebo for ABBV-7828
ABBV
AbbVie
Phase 1Recruiting
was not yet recruiting
60May 2027Registry ↗
Oct 29, 2026Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic…
NCT07592273 · Diabetic Retinopathy
Surabgene Lomparvovec, Sham
ABBV
AbbVie
Phase 2/3Recruiting576Jun 2028Registry ↗
Oct 29, 2026Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Pre…
NCT07007065 · Neovascular Age-related Macular Degeneration
Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control
ABBV
AbbVie
Phase 3Recruiting561Mar 2033Registry ↗
Oct 29, 2026A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Com…
NCT04928846 · Non Small Cell Lung Cancer, c-MET
Telisotuzumab Vedotin, Docetaxel
ABBV
AbbVie
Phase 3Recruiting768Dec 2028Registry ↗
Oct 28, 2026A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participant…
NCT06602479 · Migraine
MEDI0618, Placebo
ABBV
AbbVie
Phase 2Active, not recruiting309Feb 2027Registry ↗
Oct 28, 2026A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including…
NCT03671148 · Psoriatic Arthritis (PsA)
Placebo, Risankizumab
ABBV
AbbVie
Phase 3Active, not recruiting444Jun 22, 2020Registry ↗
Oct 27, 2026A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non…
NCT07896434 · Non-Segmental Vitiligo
Upadacitinib, Placebo for Upadacitinib
ABBV
AbbVie
Phase 3Not yet recruiting154Aug 2032Registry ↗
Oct 27, 2026Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Pos…
NCT07896421 · Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Re…
ABBV
AbbVie
—Recruiting500Apr 2030Registry ↗
Oct 27, 2026A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alo…
NCT07772492 · Severe Alopecia Areata
Upadacitinib, Placebo
ABBV
AbbVie
Phase 3Recruiting300Mar 2032Registry ↗
Oct 27, 2026Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidit…
NCT07752979 · Obesity, Overweight
ABBV-295, Placebo
ABBV
AbbVie
Phase 2Recruiting360Mar 2028Registry ↗
Oct 27, 2026A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) T…
NCT07744126 · Head and Neck Squamous Cell Carcinoma
Telisotuzumab Adizutecan, Pembrolizumab
ABBV
AbbVie
Phase 2Recruiting150Oct 2029Registry ↗
Oct 27, 2026Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Act…
NCT07697456 · Crohn's Disease, Ulcerative Colitis
Risankizumab, Trosunilimab
ABBV
AbbVie
Phase 2Recruiting2,000Oct 2031Registry ↗
Oct 27, 2026Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participant…
NCT07673107 · Upper Limb Essential Tremor
AGN-151607-DP, Placebo for AGN-151607-DP
ABBV
AbbVie
Phase 2Recruiting94Nov 2028Registry ↗
Oct 27, 2026A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous…
NCT07155174 · Small Cell Lung Cancer
ABBV-706, Atezolizumab
ABBV
AbbVie
Phase 2Recruiting180Apr 2029Registry ↗
Oct 27, 2026A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519 · Ulcerative Colitis
Risankizumab, Risankizumab
ABBV
AbbVie
Phase 3Recruiting120Jul 2034Registry ↗
Oct 27, 2026A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Com…
NCT06953960 · Multiple Myeloma
Surzetoclax, Daratumumab
ABBV
AbbVie
Phase 1/2Recruiting325Dec 2030Registry ↗
Oct 27, 2026A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizuteca…
NCT06820463 · Metastatic Colorectal Cancer
Telisotuzumab Adizutecan, Fluorouracil
ABBV
AbbVie
Phase 2Recruiting390Mar 2028Registry ↗
Oct 27, 2026Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combi…
NCT06772623 · Non Small Cell Lung Carcinoma, c-MET
Telisotuzumab Adizutecan, Budigalimab
ABBV
AbbVie
Phase 1/2Recruiting252Nov 2027Registry ↗
Oct 26, 2026A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Com…
NCT07895056 · Extensive Stage-Small Cell Lung Cancer
ABBV-706, Tarlatamab
ABBV
AbbVie
Phase 2Not yet recruiting80Aug 2031Registry ↗
Oct 26, 2026A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Com…
NCT07895043 · Extensive Stage-Small Cell Lung Cancer (ES-SCLC)
Alveltamig, Atezolizumab
ABBV
AbbVie
Phase 2Not yet recruiting80Dec 2031Registry ↗
Oct 22, 2026A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sun…
NCT07581002 · Acute Myeloid Leukemia
Pivekimab Sunirine, Venetoclax
ABBV
AbbVie
Phase 2/3Recruiting660Jun 2032Registry ↗
Oct 22, 2026Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Mod…
NCT06764706 · Ulcerative Colitis
ABBV
AbbVie
—Recruiting200Jul 2028Registry ↗
Oct 22, 2026A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399…
NCT06568939 · Non-Small Cell Lung Cancer, c-MET
Telisotuzumab Vedotin
ABBV
AbbVie
Phase 2Recruiting150Feb 2028Registry ↗
Oct 21, 2026A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination Wit…
NCT06487559 · Hepatocellular Carcinoma (HCC)
Livmoniplimab, Budigalimab
ABBV
AbbVie
Phase 1Terminated3Sep 18, 2026Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:44 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances